Transforming growth factor-β (TGF-β) is the primary factor that drives fibrosis in most, if not
all, forms of chronic kidney disease (CKD). Inhibition of the TGF-β isoform, TGF-β1, or its …

TGF-β1 has been long considered as a key mediator in renal fibrosis and induces renal
scarring largely by activating its downstream Smad signaling pathway. Interestingly, while mice …

There remains a critical need to better understand the underlying disease mechanisms
responsible for diabetes complications in order to develop new and improved therapeutic …

An elevation in circulating serum uric acid is strongly associated with the development of
hypertension and renal disease, but whether uric acid has a causal role or whether it simply …

TGF-β/Smad signaling plays a role in fibrogenesis, but therapies targeting TGF-β are ineffective
in treating renal fibrosis. Here, we explored the therapeutic potential of targeting TGF-β-…

The emergence of zerovalent atom catalysts has been highly attractive for catalytic science.
For many years, scientists have explored the stability of zerovalent atom catalysts and …

Hyperuricemia is associated with hypertension and vascular disease, but whether this represents
a causal relationship or an epiphenomenon remains unknown. We recently reported a …

Previous studies have reported that uric acid stimulates vascular smooth muscle cell (VSMC)
proliferation in vitro. We hypothesized that uric acid may also have direct proinflammatory …

It is of great urgency to develop efficient, cost-effective, stable and industrially applicable
electrocatalysts for renewable energy systems. But there are still few candidate materials. Here …

TGF-β/Smad3 signaling promotes fibrosis, but the development of therapeutic interventions
involving this pathway will require the identification and ultimate targeting of downstream …